Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1052)	2/25/1998 12:32:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2742

Hmmm..... I went back and read the release regarding the share buy back. It was supposed to close on or before 12/31....... Cistron Purchases Almost 15% of its Shares from Warner-Lambert Subsidiary PINE BROOK, N.J., Dec. 15 /PRNewswire/ -- Cistron Biotechnology, Inc. (OTC: CIST - news) has agreed to repurchase 3,946,500 shares of Cistron common stock from Med-Tech Ventures, Inc., a subsidiary of Warner-Lambert Company (NYSE: WLA - news). Med-Tech had held 4,126,365 shares and had recently sold 179,865 shares on the open market. The closing of the transaction is expected to occur on or before December 31, 1997. After giving effect to the repurchase, Cistron will have 22,983,687 shares issued and outstanding, or a reduction of 14.65% from the outstanding shares at December 12, 1997. (snip) ******************* OK, Galton/Smith, you have not given investors, in today's quarterly release, sufficient information to judge the current wisdom of their investment. We can't look at your release and determine if the buy back was delayed or canceled, or if you have diluted. To the non-suspicious mind, the numbers would imply that you have not diluted. Geeeze...... do you guys realize the degree to which your policies and strategies are non-standard? Do you clearly understand that you had (have?) the alternative route, to run your company as a competitive biotech with a clearly mapped and executed business plan?